ABSTRACT
Background The heterogeneous nature of COPD complicates the identification of the predictors of disease progression and consequently the development of effective therapies. We aimed to improve the prediction of disease progression in COPD by using machine learning and incorporating a rich dataset of phenotypic features.
Methods We included 4,496 smokers with available data from their enrollment and 5-year follow-up visits in the Genetic Epidemiology of COPD (COPDGene) study. We constructed supervised random forest models to predict 5-year progression in FEV1 from 46 baseline demographic, clinical, physiologic, and imaging features. Using cross-validation, we randomly partitioned participants into training and testing samples. We also validated the results in the COPDGene 10-year follow-up visit.
Results Predicting the change in FEV1 over time is more challenging than simply predicting the future absolute FEV1 level. Nevertheless, the area under the ROC curves for the prediction of subjects in the top quartile of observed disease progression was 0.70 in the 10-year follow-up data. The model performance accuracy was best for GOLD1-2 subjects and it was harder to achieve accurate prediction in advanced stages of the disease. Predictive variables differed in their relative importance as well as for the predictions by GOLD grade.
Conclusion This state-of-the art approach along with deep phenotyping predicts FEV1 progression with reasonable accuracy. There is significant room for improvement in future models. This prediction model facilitates the identification of smokers at increased risk for rapid disease progression. Such findings may be useful in the selection of patient populations for targeted clinical trials.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by NHLBI K08 HL141601, R01 HL124233, R01 HL126596, R01 HL147326, U01 HL089897, and U01 HL089856. The COPDGene study (NCT00608764) is also supported by the COPD Foundation through contributions made to an Industry Advisory Board that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional review board (IRB) approval was obtained. IRB Protocol Title: Genetic Epidemiology of COPD. IRB Protocol Number: Brigham and Women's Hospital / 2007P000554
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Authors’ email addresses: Adel Boueiz (adel.boueiz{at}channing.harvard.edu), Zhonghui Xu (zhonghui.xu{at}channing.harvard.edu), Yale Chang (changyalee{at}gmail.com), Aria Masoomi (masoomi.a{at}northeastern.edu), Andrew Gregory (andrew.gregory{at}channing.harvard.edu), Sharon M. Lutz (sharon.m.lutz{at}gmail.com), Dandi Qiao (dandi.qiao{at}channing.harvard.edu), James D. Crapo (CrapoJ{at}njhealth.org), Jennifer G. Dy (jdy{at}ece.neu.edu), Edwin K. Silverman (ed.silverman{at}channing.harvard.edu), Peter J. Castaldi (peter.castaldi{at}channing.harvard.edu)
Funding Sources: This work was supported by NHLBI K08 HL141601, R01 HL124233, R01 HL126596, R01 HL147326, U01 HL089897, and U01 HL089856. The COPDGene study (NCT00608764) is also supported by the COPD Foundation through contributions made to an Industry Advisory Board that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion.
Supplement: This article has an online data supplement, which is accessible from this issue’s table of content online.
Notation of prior abstract publication/presentation: Boueiz A, Chang Y, Cho MH, DeMeo DL, Dy J, Silverman EK, Castaldi PJ. Machine Learning Prediction of 5-Year Progression of FEV1 in the COPDGene Study. [abstract]. American Journal of Respiratory and Critical Care Medicine 2018;197(A7430).
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
ABBREVIATION LIST
- AUC
- Area under the curve
- BMI
- Body mass index
- COPD
- Chronic Obstructive Pulmonary Disease
- COPDGene study
- Genetic Epidemiology of COPD study
- ΔFEV1
- Annualized five-year changes in FEV1
- FEV1
- Forced expiratory volume in one second
- FVC
- Forced vital capacity
- GOLD
- Global Initiative for Chronic Obstructive Lung Disease spirometric grading system
- HU
- Hounsfield units
- IQR
- Interquartile range
- %LAA-950
- Percent of CT scan low attenuation area below -950 HU at end-inspiration
- MMRC
- Modified Medical Research Council
- NHW
- Non-Hispanic White
- RF
- Random forest
- RMSE
- Root mean squared error
- ROC
- Receiver operator characteristic
- SGRQ
- St. George’s Respiratory Questionnaire
